OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.54 SEK | -2.71% |
|
+0.12% | +6.99% |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
| Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,180 | 1,715 | 1,184 | 648.2 | 532.1 | 569.8 | - | - |
| Enterprise Value (EV) 1 | 1,707 | 1,500 | 1,173 | 791.1 | 809.5 | 858.8 | 770.8 | 682.8 |
| P/E ratio | 10.1 x | -20.4 x | -5.3 x | -3.65 x | -4.14 x | -5.32 x | -19.9 x | 12.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.58 x | 2.58 x | 2.1 x | 1.04 x | 0.83 x | 0.92 x | 0.72 x | 0.63 x |
| EV / Revenue | 2.02 x | 2.26 x | 2.08 x | 1.27 x | 1.27 x | 1.39 x | 0.98 x | 0.75 x |
| EV / EBITDA | 6.27 x | 79 x | -7.28 x | -6.87 x | -24.9 x | 45.4 x | 8.55 x | 4.19 x |
| EV / FCF | 6.7 x | -8.7 x | -4.16 x | -4.38 x | 7.65 x | -29.6 x | 77.1 x | 6.9 x |
| FCF Yield | 14.9% | -11.5% | -24% | -22.8% | 13.1% | -3.38% | 1.3% | 14.5% |
| Price to Book | 3.07 x | 3.08 x | 3.39 x | 3.34 x | 9.03 x | 19.5 x | 6.17 x | 3.79 x |
| Nbr of stocks (in thousands) | 34,711 | 34,295 | 34,328 | 34,368 | 34,421 | 34,450 | - | - |
| Reference price 2 | 62.80 | 50.00 | 34.50 | 18.86 | 15.46 | 16.54 | 16.54 | 16.54 |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 844.8 | 663.6 | 565 | 624.3 | 638.8 | 616.9 | 787.7 | 909.6 |
| EBITDA 1 | 272.1 | 19 | -161 | -115.2 | -32.5 | 18.9 | 90.2 | 163.1 |
| EBIT 1 | 231.2 | -19.9 | -214.1 | -183.9 | -109.5 | -66.2 | 14.4 | 92.4 |
| Operating Margin | 27.37% | -3% | -37.89% | -29.46% | -17.14% | -10.73% | 1.83% | 10.16% |
| Earnings before Tax (EBT) 1 | 227.9 | -38.3 | -222.5 | -170.4 | -140.3 | -114.7 | -30.1 | 47.9 |
| Net income 1 | 219.1 | -84.4 | -223.5 | -177.6 | -128.3 | -107 | -28.6 | 44.5 |
| Net margin | 25.94% | -12.72% | -39.56% | -28.45% | -20.08% | -17.34% | -3.63% | 4.89% |
| EPS 2 | 6.200 | -2.450 | -6.510 | -5.170 | -3.730 | -3.110 | -0.8300 | 1.290 |
| Free Cash Flow 1 | 255 | -172.4 | -281.9 | -180.5 | 105.8 | -29 | 10 | 99 |
| FCF margin | 30.18% | -25.98% | -49.89% | -28.91% | 16.56% | -4.7% | 1.27% | 10.88% |
| FCF Conversion (EBITDA) | 93.72% | - | - | - | - | - | 11.09% | 60.7% |
| FCF Conversion (Net income) | 116.39% | - | - | - | - | - | - | 222.47% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 145.9 | 144 | - | 156.1 | 158.8 | 157.7 | 156.1 | 166 | 144.4 | 155.6 | 156.8 | 160 |
| EBITDA 1 | -47.4 | -48.5 | - | -53.1 | -41.1 | 5.6 | -9.5 | 12.4 | 6.3 | 2.1 | 5 | 5.5 |
| EBIT 1 | -59 | -64.1 | - | -71.1 | -59.3 | -12.9 | -28.6 | -8.6 | -14.9 | -19.2 | -16.3 | -15.8 |
| Operating Margin | -40.44% | -44.51% | - | -45.55% | -37.34% | -8.18% | -18.32% | -5.18% | -10.32% | -12.34% | -10.4% | -9.88% |
| Earnings before Tax (EBT) 1 | -59.1 | - | - | -95.5 | -68.5 | -15.8 | -36.6 | -19.5 | -27.4 | -31.7 | -28.3 | -27.3 |
| Net income 1 | -52 | -66 | -26.5 | -91.8 | -63.9 | -12.6 | -33.3 | -18.6 | -26.6 | -29.8 | -26 | -24.5 |
| Net margin | -35.64% | -45.83% | - | -58.81% | -40.24% | -7.99% | -21.33% | -11.2% | -18.42% | -19.15% | -16.58% | -15.31% |
| EPS 2 | -1.510 | -1.920 | -0.7700 | -2.670 | -1.860 | -0.3700 | -0.9700 | -0.5400 | -0.7700 | -0.8700 | -0.7600 | -0.7100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 1/27/22 | 11/3/22 | 1/26/23 | 4/27/23 | 7/18/23 | 11/2/23 | 2/8/24 | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 143 | 277 | 289 | 201 | 113 |
| Net Cash position 1 | 473 | 214 | 11.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -1.24 x | -8.535 x | 15.29 x | 2.228 x | 0.6928 x |
| Free Cash Flow 1 | 255 | -172 | -282 | -181 | 106 | -29 | 10 | 99 |
| ROE (net income / shareholders' equity) | 37.1% | -13.3% | -49.2% | -65.4% | - | - | - | 36.7% |
| ROA (Net income/ Total Assets) | 15.7% | -6.17% | -17.8% | -14.9% | - | - | - | - |
| Assets 1 | 1,394 | 1,367 | 1,253 | 1,191 | - | - | - | - |
| Book Value Per Share 2 | 20.40 | 16.20 | 10.20 | 5.640 | 1.710 | 0.8500 | 2.680 | 4.360 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 35.9 | 190 | 52.9 | 23.9 | - | 3 | 8 | 11 |
| Capex / Sales | 4.25% | 28.6% | 9.36% | 3.83% | - | 0.49% | 1.02% | 1.21% |
| Announcement Date | 1/30/20 | 1/28/21 | 1/27/22 | 1/26/23 | 2/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.99% | 51.97M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- ORX Stock
- Financials Orexo AB
